Hims & Hers Health Drops 5.8% After Barclays Maintains Overweight

U.S. stock futures were mixed on Tuesday, with Nasdaq and Russell 2000 futures up 0.1%, Dow futures down 0.1%, and S&P 500 futures flat. Investors await July CPI data and geopolitical tensions impact sentiment. Key earnings reports include SMCI, CRWV, CAVA, LITE, and SLS. NVDA labeled AI data centers as investable assets, INTC upsized its share sale to $20B, and RIOT secured a $9.1B deal. RKLB shares fell despite a revenue beat, ASTS extended selloff, and SPCX faced lockup expiration pressures.

The FTC and state regulators sued Hims & Hers Health, alleging deceptive practices in its telehealth subscription model and sharing of sensitive health data with third-party advertisers. The complaint claims Hims misled consumers about privacy, made cancellations difficult, and failed to disclose data-sharing practices. The case highlights expanding privacy risks for digital health companies under consumer-protection laws.

Hims & Hers Health (HIMS) stock fell 14.73% to $25.00 after the FTC sued the company for alleged privacy violations and deceptive billing practices. The lawsuit claims HIMS shared user health data with third parties and enrolled consumers in subscriptions without proper consent. Hagens Berman is investigating potential securities law violations and financial reporting inaccuracies.

Visa (V) placed Hims & Hers (HIMS) in its Acquirer Monitoring Program due to elevated credit card disputes, imposing an $8 surcharge per dispute. This adds to HIMS's margin and regulatory concerns, though strong weight-loss demand and short interest may provide upside. Visa's action highlights HIMS's customer retention issues and potential profitability risks.

U.S. stock futures are mixed as oil prices surge past $100/barrel and new tariffs are announced. Intel (INTC) and Oracle (ORCL) gained premarket after positive news, while Tesla (TSLA) rebounded slightly. SpaceX (SPCX) fell to 52-week lows. Key economic data and earnings reports are expected later.

FDA reports over 1,700 adverse events linked to compounded semaglutide and tirzepatide. MEDVi, a company in the compounded GLP-1 market, faced FDA warnings and legal challenges. Novo Nordisk and Lilly have sued over patent infringement. The industry faces regulatory scrutiny and potential legislative changes.